FDA

Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding its heart failure treatment.
Myovant shares shot up on Monday after the company announced a new collaboration with Pfizer for its tumor treatment across a couple of indications.
Altimmune shares dropped on Thursday after the company announced that it had received an update from the FDA regarding its COVID-19 vaccine candidate.
Galapagos was crushed on Wednesday after the firm, in conjunction with Gilead, announced a new commercialization and development agreement for their Rheumatoid Arthritis (RA) treatment.
BioNTech was in the spotlight on Tuesday after it received a sizable price target hike from one key analyst.
After scPhamaceuticals announced that it had received a Complete Response Letter from the FDA, its shares were absolutely crushed on Monday.
Vanda Pharma shares jumped on Wednesday after the company announced an update from the FDA regarding its treatment for nighttime sleep disturbances associated with Smith-Magenis syndrome.
Moderna shares continued to run higher on Monday after the company announced an update for the primary efficacy analysis for its late-stage coronavirus vaccine trial.
24/7 Wall St. has tracked multiple analyst calls regarding the expected approval or nonapproval of aducanumab as the first viable treatment against Alzheimer's disease.
Biogen shares rocketed up on Wednesday after briefing documents from the FDA provided evidence of the effectiveness of the firm’s Alzheimer’s disease treatment.
DBV Technologies is making a comeback after making headway for its peanut allergy treatment in Europe.
The novel coronavirus has wiped out trillions of dollars in global output with more than 1 million deaths worldwide in 2020. With cases rising rapidly in the United States and in Europe, more...
Gilead Sciences is the first company to cross the finish line for regulatory approval in the fight against the coronavirus.
OraSure Technologies shares jumped to start off the week after the company announced an update from the FDA in regards to its COVID-19 test kit.
Eli Lilly shares made a handy gain on Wednesday after the company announced an update to its SARS-CoV-2 neutralizing antibody programs.